Proactiveinvestors is a leading multi-media news organisation, investor portal and events management business with offices in New York, Sydney, Toronto, Frankfurt and London.
Thursday, 21 March 2013
NanoViricides to present at key BioPhysics seminar this week
NanoViricides (OTCBB:NNVC) says that its president, Dr. Anil Diwan, will present at a seminar later this week at the University of California in Los Angeles, which will be hosted by the Center for Biological Physics and with the California NanoSystems Institute.
Dr. Diwan's talk, entitled "Designing a Nanoviricide - Biophysics is the Key" will take place on Friday March 22nd, the company said in a statement Wednesday.
"I am honored to have this opportunity to discuss our work with eminent biophysicists that are researching the interactions and structural stability of viruses," said Dr. Diwan. "Biophysics is the key to understanding our approach to developNanoViricides, our novel biomimetic agents designed to destroy viruses."
Including the company's FluCide program, NanoViricidescurrently has six “commercially important” drug candidates in its pipeline that together address a market size greater than $40 billion. Those include drugs for use against HIV, viral eye diseases, Herpes, and Dengue viruses.
Its drugs use NanoViricides, which are a biomimetic decoy designed to fool a virus particle into binding to it and thereby capturing the virus particle and rendering it harmless.
Its FluCide program consists of the injectable anti-flu drug, NV-INF-1,
which is intended for use in hospitalized patients with the flu, and its oral anti-influenza candidate, NV-INF-2, which may be the first ever nanomedicine drug of any kind that is active when administered orally.
Both drugs have shown “very high effectiveness” in preclinical animal studies, NanoViricides noted, routinely showing substantial superiority to Tamiflu, the current standard of care.
The company has also said that a single course treatment for out-patients is a "highly sought after" goal in flu therapeutics and that it estimates the market size for anti-influenza drugs to be roughly $4 to $7 billion worldwide. NanoViricides said it believes that if its FluCide drugs become available, the influenza drug market size could expand substantially.
The company, which is in the midst of a renovation project at its facility in Connecticut, said Wednesday that the challenges and opportunities for understanding the behaviour of virus-nanoviricde interactions, and the results of nanoviricide studies against various viruses, will be discussed at the seminar later this week.